TRAF2 and hepatocellular carcinoma: Several studies have found that TRAF2 is upregulated in various types of cancers, including hepatocellular carcinoma (Liang et al., 2023), esophageal squamous cell carcinoma (Zhang T. et al., 2024), lung squamous cell carcinoma (Nguyen et al., 2024), colorectal cancer (Teng et al., 2024), lymphoma (Vashisht et al., 2023), renal cell carcinoma (Ge et al., 2023), ovarian carcinoma (Zheng et al., 2022), and gastric carcinoma (Rossi et al., 2022).